Souhaitez-vous accéder aux communiqués récents ?

Poursuite du recentrage stratégique dans un environnement de marché contrasté Chiffre d’affaires de 892,4 M€ en 2025 (-5,4 % vs. 2024 retraité1)Marge d’EBITDA ajusté à 7,3 %, (-60 pb)Trésorerie brute...

Continued strategic refocusing in a challenging market environment Revenue of €892.4 million in 2025 (-5.4% vs. 2024 restated1)Adjusted EBITDA margin of 7.3% (-60 bp)Gross cash of €73.2 million and...

Ci-joint le rapport financier annuel - ESEF en français qui est la version officielle. Pièce jointe solutions30-2025-12-31-fr ...

Please find attached the annual report (ESEF format) in English, for information only. The French version is the official one. Attachment solutions30-2025-12-31-en ...

2025 Annual Results Strong Revenue Growth in 2025: up 14% with Subscriptions up 20% Record Profitability: EBITDA up 22% to €13.4 million, Representing 22% of Revenue (+2 pts) Operating Leverage...

Résultats annuels 2025 Forte croissance du CA en 2025 : +14% dont +20% pour les abonnements Record historique de rentabilité : EBITDA en hausse de 22% à 13,4 M€, soit 22% du CA (+2 pts) Effet de...

IRVING, Texas, March 30, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company orchestrating...

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the...

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports...

HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider and crypto...